Tc-99m Sestamibi and In-111 Pentetreotide Uptake in Metastatic Papillary Thyroid Carcinoma

Approximately 25% of metastatic and recurrent differentiated (papillary and follicular) thyroid carcinoma do not concentrate I-131 Nal. In such cases, diagnosis can be attempted with other radiopharmaceuticals. The authors present a case of recurrent papillary thyroid carcinoma that was well visuali...

Full description

Saved in:
Bibliographic Details
Published in:Clinical nuclear medicine 1995-10, Vol.20 (10), p.867-868
Main Authors: LEE, JOHN, CUTRONE, JOHN A, MARCUS, CAROL S
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Carcinoma, Papillary - diagnostic imaging
Carcinoma, Papillary - secondary
Female
Humans
Indium Radioisotopes
Neoplasm Recurrence, Local - diagnostic imaging
Radionuclide Imaging
Technetium Tc 99m Sestamibi
Thyroid Neoplasms - diagnostic imaging
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Approximately 25% of metastatic and recurrent differentiated (papillary and follicular) thyroid carcinoma do not concentrate I-131 Nal. In such cases, diagnosis can be attempted with other radiopharmaceuticals. The authors present a case of recurrent papillary thyroid carcinoma that was well visualized with Tc-99m sestamibi and ln-111 pentetreotide; but only poorly visualized by I-131 Nal.
ISSN:0363-9762
1536-0229
DOI:10.1097/00003072-199510000-00001